C71T
CANCELLED SECTION 71
01/23/2026
Back to search
Official data from USPTO
CURADIGM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
35
Latest update
02/17/2026
Trademark type
Combined
Nice classes
5, 10, 42, 44
Filing date
08/01/2018
Registration date
07/09/2019
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
01/23/2026
Last transaction
02/17/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
5
Owner type
84
Owner location
FR
Examiner
BROWN, TRICIA
Law office
N30
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
NANOBIOTIX
CURADIGM
Representatives
Dreyfus & associés
Technical classification
Nice Classes
Class 5Class 10Class 42Class 44
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Products for medical use especially for metabolic pathwaysenzyme substrates and enzyme inhibitors; products for medical use especially for the diagnosis and treatment of tumorsdiagnostic preparation for medical purposes for the diagnosis of tumors and therapeutic pharmaceutical preparations for medical purposes for the treatment of tumors and rare hepatic diseases; preparations for medical use especially for modifying the bioavailability of therapeutic agentslipidic and polymeric formulation for drug delivery in the nature of drug delivery agents in the form of nanoparticlesnanovesiclesparticlesvesiclesdissolvable filmscoatings for tablets and hydrogels that facilitate the delivery of pharmaceutical preparations; preparations for medical use especially for modifying liver functionspharmaceutical preparations for the treatment of liver diseases and disorders and pharmaceutical preparations to alter hepatic metabolization pathways; preparations for medical use for modifying the functions of the reticuloendothelial systempharmaceutical preparations for the treatment of reticuloendothelial system diseases and disorders and pharmaceutical preparations to alter reticuloendothelial system endocytosis pathways; preparations made with nanomaterials for the delivery of therapeutic agentsdrug delivery agents in the form of enterallyparenterally in the nature of intravenoustopically administered nanomaterials that facilitate the delivery of pharmaceutical preparations; chemical reagents for medical use; bacteriological preparations for medical use; biological preparations for medical use for the treatment of cancercentral nervous system disorderscardiologicalimmunologicalgastrointestinalmetabolic and infection diseases; enzymes for medical use; enzyme preparations for medical use; chemical preparations for medical or pharmaceutical usefor the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infection diseases; diagnostic products for medical usediagnostic preparations for medical purposes; drugs for medical usemedical preparations for the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infectious diseases; medicines for human medicinemedical preparations for the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infectious diseases; tonics medicinesmedical herbal preparations; antibiotics; antiseptics; chemico-pharmaceutical products for the treatment of the treatment of cancercentral nervous system disordercardiologicalimmunologicalgastrointestinalmetabolic and infection diseases; pharmaceutical productsdrug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; dietetic substances for medical usedietetic foods adapted for medical purposes; remedies for human medicinenatural remedy preparations for the treatment of gastrointestinal conditionshormonal and chemical imbalancessleep disorders
Class 10
Surgical and medical apparatus and instruments especially for the diagnosis and treatment of tumors; Surgical and medical apparatus and instruments especially for monitoring and modifying metabolic functions; Apparatus for modifying the functions of the reticuloendothelial systemmedical apparatus and instruments for use in endovascular and cardiovascular procedures; Apparatus for modulating liver functionsmedical apparatus and instruments for use in measuringquantifying and assessing liver health and oxygenation and perfusion apparatus in the nature of perfusion pumps for liver transplantation; Apparatus for the delivery of therapeutic or diagnostic agentsmedical apparatus and units for dosagemeasuring and monitoringin the nature of drug delivery devices and systemsorgan oxygenation and perfusion apparatus in the nature of perfusion pumps; Apparatus for modulating hepatic blood floworgan perfusion apparatus in the nature of perfusion pumps; Testing apparatus for medical use in the nature of medical diagnostic apparatus for testing cancer callsDNAorgan oxygenation and blood sugar levels; Diagnostic apparatus for medical use for testing cancer callsDNAorgan oxygenation and blood sugar levels
Class 42
Scientific and technological servicesresearch and design especially in the field of nanomedicinein the nature of nanotechnology applied to medicine; Biological research services; Bacteriological research services; Evaluationsestimates and research in scientific and technological fields provided by engineers and researchersconducting early evaluations in the field of new pharmaceuticals; Design and development of new products for third parties in the field of pharmaceutical preparations and diagnostic devices design; Technical research in the field of pharmaceutical project studies; Industrial analysis and research servicesbiomedical research services; Chemical analysis; Chemical research; Chemistry serviceschemistry consultation; Surveyingengineering work; Research and development of new products for others; Technical research in the field of pharmaceutical studies; Biological researchradiobiology researchbiologicalpharmacokineticpharmacodynamic and immunological evaluation and toxicological evaluation; Medical researchresearch in nanoscience and nanotechnologyespecially applied to medicine
Class 44
Healthcare especially in the field of nanomedicine; medical services especially in the field of nanomedicine; hospital services; medical assistance; physiotherapy
Publications
History of USPTO decisions and trademark events.
35 publications found
CHLD
CHANGE OF OWNER RECEIVED FROM IB
12/27/2024
CHLD
CHANGE OF OWNER RECEIVED FROM IB
02/27/2020
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
11/15/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/29/2019
FIMP
FINAL DISPOSITION PROCESSED
10/29/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/09/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
07/09/2019
GPNX
NOTIFICATION PROCESSED BY IB
05/03/2019
PUBO
PUBLISHED FOR OPPOSITION
04/23/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/17/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/17/2019
NPUB
NOTICE OF PUBLICATION
04/03/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/15/2019
CNEA
EXAMINERS AMENDMENT MAILED
03/15/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
03/14/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
03/14/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/07/2019
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
03/07/2019
CNFR
FINAL REFUSAL MAILED
03/04/2019
CNFR
FINAL REFUSAL WRITTEN
03/01/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/08/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/08/2019
ALIE
ASSIGNED TO LIE
02/07/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
02/03/2019
RFNT
REFUSAL PROCESSED BY IB
12/21/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
12/04/2018
RFRR
REFUSAL PROCESSED BY MPU
12/04/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
11/19/2018
CNRT
NON-FINAL ACTION WRITTEN
11/18/2018
DOCK
ASSIGNED TO EXAMINER
11/18/2018
MAFR
APPLICATION FILING RECEIPT MAILED
11/13/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
11/07/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
11/01/2018
Continuous trademark protection
Get notified about every new filing that threatens CURADIGM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.